Salie Maasewerd

Salie Maasewerd

Auto-generated profile, based on publicly available information

Salie Maasewerd

Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
DBDamien Bertheloot
Damien Bertheloot
CWCarlos Ws Wanderley
Carlos Ws Wanderley
ASAyda H Schneider
Ayda H Schneider
LSLisa Dj Schiffelers
Lisa Dj Schiffelers
JWJennifer Deborah Wuerth
Jennifer Deborah Wuerth
BFBernardo S Franklin
Bernardo S Franklin
Inflammasomes sense intracellular clues of infection, damage, or metabolic imbalances. Activated inflammasome sensors polymerize the adaptor ASC into micron‐sized “specks” to maximize caspase‐1 activation and the maturation of IL‐1 cytokines. Caspase‐1 also drives pyroptosis, a lytic cell death characterized by leakage of intracellular content to the extracellular space. ASC specks are released among cytosolic content, and accumulate in tissues of patients with chronic inflammation. However, if extracellular ASC specks contribute to disease, or are merely inert remnants of cell death remains unknown. Here, we show that camelid‐derived nanobodies against ASC (VHH ASC ) target and disassemble post‐pyroptotic inflammasomes, neutralizing their prionoid, and inflammatory functions. Notably, pyroptosis‐driven membrane perforation and exposure of ASC specks to the extracellular environment allowed VHH ASC to target inflammasomes while preserving pre‐pyroptotic IL‐1β release, essential to host defense. Systemically administrated mouse‐specific VHH ASC attenuated inflammation and clinical gout, and antigen‐induced arthritis disease. Hence, VHH ASC neutralized post‐pyroptotic inflammasomes revealing a previously unappreciated role for these complexes in disease. VHH ASC are the first biologicals that disassemble pre‐formed inflammasomes while preserving their functions in host defense.

8 July 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
IHIbrahim Hawwari
Ibrahim Hawwari
LRLukas Rossnagel
Lukas Rossnagel
NRNathalia Rosero
Nathalia Rosero
SMSalie Maasewerd
Salie Maasewerd
MVMatilde B Vasconcelos
Matilde B Vasconcelos
BFBernardo S Franklin
Bernardo S Franklin
In humans, blood Classical CD14 + monocytes contribute to host defense by secreting large amounts of pro-inflammatory cytokines. Their aberrant activity causes hyper-inflammation and life-threatening cytokine storms, while dysfunctional monocytes are associated with ‘immunoparalysis’, a state of immune hypo responsiveness and reduced pro-inflammatory gene expression, predisposing individuals to opportunistic infections. Understanding how monocyte functions are regulated is critical to prevent these harmful outcomes. We reveal platelets’ vital role in the pro-inflammatory cytokine responses of human monocytes. Naturally low platelet counts in patients with immune thrombocytopenia or removal of platelets from healthy monocytes result in monocyte immunoparalysis, marked by impaired cytokine response to immune challenge and weakened host defense transcriptional programs. Remarkably, supplementing monocytes with fresh platelets reverses these conditions. We discovered that platelets serve as reservoirs of key cytokine transcription regulators, such as NF-κB and MAPK p38, and pinpointed the enrichment of platelet NF-κB2 in human monocytes by proteomics. Platelets proportionally restore impaired cytokine production in human monocytes lacking MAPK p38α, NF-κB p65, and NF-κB2. We uncovered a vesicle-mediated platelet-monocyte-propagation of inflammatory transcription regulators, positioning platelets as central checkpoints in monocyte inflammation.

30 July 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
SMSalie Maasewerd
Salie Maasewerd
BFBernardo S Franklin
Bernardo S Franklin
Currently, over 350 million people worldwide live with chronic inflammatory diseases, facing a range of complications that severely impact their quality of life. Among these complications is amyloidosis, a group of diseases characterized by the extracellular deposition of insoluble amyloid fibrils that disrupt tissue structure and function. One specific form, amyloid A (AA) amyloidosis, is closely linked to chronic inflammatory conditions such as rheumatoid arthritis (RA), Familial Mediterranean Fever (FMF), Crohn’s disease, and chronic infections. In this issue of EMBO Mol Med, Losa et al, shows that the inflammasome adaptor ASC plays an important role in the pathogenesis of AA amyloidosis, and suggests a potential immunotherapy for treating the disease (Losa et al, 2024).